Loading...
•
Mar 31, 2022
Adicet Bio Q1 2022 Earnings Report
Reported financial results and operational highlights for the first quarter ended March 31, 2022.
Key Takeaways
Adicet Bio reported a net income of $4.6 million for the first quarter of 2022, which includes non-cash stock-based compensation expense of $4.4 million, and cash and cash equivalents of $277.9 million as of March 31, 2022.
ADI-001 Phase 1 trial data accepted for oral presentation at 2022 ASCO Annual Meeting.
Strong balance sheet with $277.9 million in cash and cash equivalents as of March 31, 2022.
FDA granted Fast Track Designation to ADI-001 for potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma (NHL).
Regeneron licensed the exclusive, worldwide rights to ADI-002 and paid an exercise fee of $20.0 million to Adicet.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...